CN112770749A - 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用 - Google Patents

双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用 Download PDF

Info

Publication number
CN112770749A
CN112770749A CN201980047382.4A CN201980047382A CN112770749A CN 112770749 A CN112770749 A CN 112770749A CN 201980047382 A CN201980047382 A CN 201980047382A CN 112770749 A CN112770749 A CN 112770749A
Authority
CN
China
Prior art keywords
berberine
diabetes
bifidobacterium
bifidobacteria
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980047382.4A
Other languages
English (en)
Inventor
姬秋和
王晓凯
明洁
徐晓强
夏炎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Aimigene Technology Co ltd
Fourth Military Medical University FMMU
Original Assignee
Shenzhen Aimigene Technology Co ltd
Fourth Military Medical University FMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Aimigene Technology Co ltd, Fourth Military Medical University FMMU filed Critical Shenzhen Aimigene Technology Co ltd
Publication of CN112770749A publication Critical patent/CN112770749A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及双歧杆菌和黄连素在制备一种治疗糖尿病前期或2型糖尿病的药物中的用途。具体地，本发明的药物联用适用于糖尿病前期患者或5.6≤空腹血糖值(FPG)<8.0mmol/L或7.8≤OGTT后两小时静脉血糖<17mmol/L的2型糖尿病患者。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980047382.4A 2018-07-17 2019-07-16 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用 Pending CN112770749A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018107813862 2018-07-17
CN201810781386.2A CN110721203A (zh) 2018-07-17 2018-07-17 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用
PCT/CN2019/096102 WO2020015622A1 (zh) 2018-07-17 2019-07-16 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用

Publications (1)

Publication Number Publication Date
CN112770749A true CN112770749A (zh) 2021-05-07

Family

ID=69163854

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810781386.2A Pending CN110721203A (zh) 2018-07-17 2018-07-17 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用
CN201980047382.4A Pending CN112770749A (zh) 2018-07-17 2019-07-16 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810781386.2A Pending CN110721203A (zh) 2018-07-17 2018-07-17 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用

Country Status (3)

Country Link
US (1) US20220202882A1 (zh)
CN (2) CN110721203A (zh)
WO (1) WO2020015622A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113151103A (zh) * 2021-05-14 2021-07-23 山西农业大学 一株具有缓解ⅱ型糖尿病功效的短乳杆菌及其应用
CN116077536A (zh) * 2023-03-17 2023-05-09 微康益生菌(苏州)股份有限公司 一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113884684B (zh) * 2021-09-10 2023-09-15 上海依赛洛森生物医药有限公司 一种活动性结核病多组学整合标志物、试剂盒及检测模型的构建方法
CN115838661A (zh) * 2022-10-20 2023-03-24 河北御芝林药业有限公司 一种植物乳杆菌扁鹊君18、植物乳杆菌制剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670661A (zh) * 2011-03-08 2012-09-19 惠宏襄 用于刺激胰高血糖素样肽-1分泌的药物
CN106474123A (zh) * 2016-08-31 2017-03-08 胡建华 一种纳米黄连素片
CN107109348A (zh) * 2014-08-29 2017-08-29 科.汉森有限公司 益生菌青春双歧杆菌菌株

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130097789A (ko) * 2010-10-15 2013-09-03 코넬 유니버시티 내분비, 위장관 또는 자가면역 장애 치료를 위한 조성물 및 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670661A (zh) * 2011-03-08 2012-09-19 惠宏襄 用于刺激胰高血糖素样肽-1分泌的药物
CN107109348A (zh) * 2014-08-29 2017-08-29 科.汉森有限公司 益生菌青春双歧杆菌菌株
CN106474123A (zh) * 2016-08-31 2017-03-08 胡建华 一种纳米黄连素片

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIE MING等: "Effectiveness and safety of bifidobacteria and berberine in people with hyperglycemia: study protocol for a randomized controlled trial", vol. 19, no. 19, pages 1 - 8 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113151103A (zh) * 2021-05-14 2021-07-23 山西农业大学 一株具有缓解ⅱ型糖尿病功效的短乳杆菌及其应用
CN113151103B (zh) * 2021-05-14 2022-11-18 山西农业大学 一株具有缓解ⅱ型糖尿病功效的短乳杆菌及其应用
CN116077536A (zh) * 2023-03-17 2023-05-09 微康益生菌(苏州)股份有限公司 一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用
CN116077536B (zh) * 2023-03-17 2023-11-28 微康益生菌(苏州)股份有限公司 一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用

Also Published As

Publication number Publication date
WO2020015622A1 (zh) 2020-01-23
CN110721203A (zh) 2020-01-24
US20220202882A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
Dehghan et al. Impact of prebiotic supplementation on T-cell subsets and their related cytokines, anthropometric features and blood pressure in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial
CN112770749A (zh) 双歧杆菌与黄连素联用对糖尿病前期和2型糖尿病的作用
CN110150669B (zh) 一种适于糖尿病患者食用的益生菌组合物及其应用
EP3120858B1 (en) Supplementation of maternal diet
Rezaei et al. The effect of probiotic yogurt on blood glucose and cardiovascular biomarkers in patients with type II diabetes: a randomized controlled trial
EP2766026B1 (en) Prevention and diagnosis of visceral fat
CN107106584A (zh) 用于治疗代谢障碍的合成组合物
CN104413334A (zh) 可食用组合物及其制备方法和用途
US20200376044A1 (en) Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics
JP5758629B2 (ja) 消化器疾患に関連する症状の緩和に使用されるプロバイオティクス
JP2022001572A (ja) 漢方処方菌叢カプセル、その製造方法、及び２型糖尿病の治療薬の製造における漢方処方菌叢カプセルの使用
TWI671017B (zh) 組合包在製備用於改善和治療人類小胖威利綜合症的藥品中的應用
KR20200023432A (ko) 신장질환을 가진 환자에서 신장 기능을 유지시키고 및 개선시키는 방법 및 표준 관리 치료 방법
US20220105141A1 (en) Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof
CN110448569B (zh) 一种具有止泻功效的组合物及其制备方法和其应用
AU2021218215A1 (en) Enzyme composition for management of metabolic health
TWI667344B (zh) Lactobacillus reuteri strain GMNL-263 and composition thereof capable of improving hypertension
US20190388484A1 (en) Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof
Murti Probiotic Usage as Therapy on Diabetes Mellitus Type II. A Literature Review
Heidary et al. Crohn's disease and nursing care from a patient treated with corticosteroids: a case report
García et al. Metabolic Shifting Probiotic in Type 2 Diabetes Mellitus Management: Randomized Clinical Trial
CN110384719B (zh) 可改善高血压的罗伊氏乳杆菌菌株gmnl-263及其组合物
Bahaa Eldin et al. Assessment of TNF Alpha in Type 2 Diabetic Patients with Lactobacillus Acidophilus
CN116726011A (zh) 艾普拉唑用于调节消化道微生态的用途
Melnychuk et al. Holter ECG monitoring and gut microbiota composition in coronary artery disease patients with atrial fibrillation| Ukrainian Medical Journal

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: No. 169, Changle West Road, Xi'an, Shaanxi 710000

Applicant after: Air Force Medical University

Applicant after: Shenzhen zero one life Technology Co.,Ltd.

Address before: 710032 No. 169 West Changle Road, Shaanxi, Xi'an

Applicant before: THE FOURTH MILITARY MEDICAL University

Applicant before: SHENZHEN AIMIGENE TECHNOLOGY Co.,Ltd.